Edward A. Gill

Edward A. Gill

Auto-generated profile, based on publicly available information

Edward A. Gill

Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, USA (Gill)

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2023 in Chest
Verified
Journal Article
Closed access
ALAugust Longino
August Longino
KMKatie Martin
Katie Martin
KLKatarina Leyba
Katarina Leyba
GSGabriel Siegel
Gabriel Siegel
TTTheresa N. Thai
Theresa N. Thai
JBJoseph Burke
Joseph Burke

12 May 2023 in Circulation Research
Verified
Journal Article
Closed access
NANatasha L. Altman
Natasha L. Altman
ABAmber A. Berning
Amber A. Berning
SMSarah C. Mann
Sarah C. Mann
RQRobert A. Quaife
Robert A. Quaife
EGEdward A. Gill
Edward A. Gill
MBMichael R. Bristow
Michael R. Bristow
SARS-CoV-2 vaccine–associated myocarditis/myocardial injury should be evaluated in the contexts of COVID-19 infection, other types of viral myocarditis, and other vaccine-associated cardiac disorders. COVID-19 vaccine–associated myocardial injury can be caused by an inflammatory immune cell infiltrate, but other etiologies such as microvascular thrombosis are also possible. The clinical diagnosis is typically based on symptoms and cardiac magnetic resonance imaging. Endomyocardial biopsy is confirmatory for myocarditis, but may not show an inflammatory infiltrate because of rapid resolution or a non-inflammatory etiology. Myocarditis associated with SARS-COVID-19 vaccines occurs primarily with mRNA platform vaccines, which are also the most effective. In persons aged >16 or >12 years the myocarditis estimated crude incidences after the first 2 doses of BNT162b2 and mRNA-1273 are approximately 1.9 and 3.5 per 100 000 individuals, respectively. These rates equate to excess incidences above control populations of approximately 1.2 (BNT162b2) and 1.9 (mRNA-1273) per 100 000 persons, which are lower than the myocarditis rate for smallpox but higher than that for influenza vaccines. In the studies that have included mRNA vaccine and SARS-COVID-19 myocarditis measured by the same methodology, the incidence rate was increased by 3.5-fold over control in COVID-19 compared with 1.5-fold for BNT162b2 and 6.2-fold for mRNA-1273. However, mortality and major morbidity are less and recovery is faster with mRNA vaccine–associated myocarditis compared to COVID-19 infection. The reasons for this include vaccine-associated myocarditis having a higher incidence in young adults and adolescents, typically no involvement of other organs in vaccine-associated myocarditis, and based on comparisons to non-COVID viral myocarditis an inherently more benign clinical course.

29 January 2026 in JACC: Advances
Verified
Journal Article
Open access
KLKatarina Leyba
Katarina Leyba
ALAugust Longino
August Longino
RORyen Ormesher
Ryen Ormesher
MKMary Krienke
Mary Krienke
NONatalie Van Ochten
Natalie Van Ochten
EGEdward Gill
Edward Gill
Venous excess ultrasound score (VExUS) is an emerging point-of-care ultrasound tool to evaluate venous congestion using inferior vena cava (IVC) diameter and hepatic vein pulse-wave Doppler. The utility of VExUS to detect changes in intravascular volume is not well established. The objective of the study was to investigate the ability of a standardized point-of-care ultrasound exam to capture dynamic changes in volume status. This was a prospective observational study of inpatients with end-stage renal disease. Patients underwent VExUS exams before and after hemodialysis (HD). Patient with an IVC diameter 2 cm, the scores of the component were totaled for a composite score. The primary outcome was change in composite VExUS score. A univariate linear regression analysis was used to evaluate for a linear relationship between the volume of fluid removed and change in composite VExUS score. Forty-six patients (92 paired ultrasound exams) were included. The median volume of fluid removed with HD was 2,000 mL (IQR: 985-2,500 mL). Wilcoxon signed-rank test of pre-HD and post-HD VExUS scores revealed a median score decrease of 1.5 (95% CI: 1-2; P < 0.001) on a VExUS scale ranging from 0 to 4. There was not a significant linear relationship between volume removed and change in VExUS score. Fluid removal with HD was associated with changes in the VExUS score, highlighting the utility of VExUS to capture dynamic shifts in intravascular volume in patients with end-stage renal disease.

15 December 2021 in Echocardiography
Verified
Journal Article
Closed access
PDF file
GHGary S. Huang
Gary S. Huang
FSFlorence H. Sheehan
Florence H. Sheehan
EGEdward A. Gill
Edward A. Gill


1 May 2012 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
EGEdward A. Gill
Edward A. Gill
MCMichael A. Chen
Michael A. Chen
ATArthi Thirumalai
Arthi Thirumalai
BFBrian Fish
Brian Fish
PPPathmaja Paramsothy
Pathmaja Paramsothy